Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

Share Price is delayed by 15 minutes
Get Live Data
28.75    0.00 (0.00%)
Bid:
28.50
Ask:
29.00
Spread: 0.50 (1.754%)
Market Cap: £121.51m
MERC Live PriceLast checked at - London Stock Exchange

Intraday Mercia Asset Share Chart

Amendment : Form 8.3 - Merchant Securities plc

11 Nov 2011 12:46

Please be advised that this announcement updates the earlier one published at 12:26 today.The earlier issued announecment omitted the name of the relevant securities in Section 1.(c)This has been corrected. All other information contained within remains the same. FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/dealings are VFT LTD

being disclosed: Robin Lemer Benjamin Lemer

(b) Owner or controller of interests and short positions VFT LTD Owned disclosed, if different from 1(a): by Lemer Family The naming of nominee or vehicle companies is

insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Merchant Securities plc Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/ offeree, state this and specify identity of offeror/

offeree:

(e) Date position held/dealing undertaken: 10/11/11 (f) Has the discloser previously disclosed, or are they NO: today disclosing, under the Code in respect of any other party to this offer?

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Interests Short positions Number % Number % (1) Relevant securities owned 1090000 2.097 and/or controlled: (2) Derivatives (other than options): (3) Options and agreements to purchase/sell: TOTAL: 1090000 2.097

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right

exists:

Details, including nature of the

rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities 1P Ordinary Purchase 250,000 21.2p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description e.g. opening/closing a reference unit security e.g. CFD long/short position, securities increasing/reducing a long/short position

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price e.g. date money security e.g. call selling, to which per unit American, paid/ option varying option European received etc. relates etc. per unit (ii) Exercising

Class of relevant Product Number of Exercise price

per security description securities unit e.g. call option

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit security e.g. subscription, (if applicable) conversion

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or

understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person

making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none" None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal,

between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 11/11/11 Contact name: Robin Lemer 0207 739 6568

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

XLON
Date   Source Headline
27th Oct 20217:00 amRNSNotice of Interim Results
26th Oct 20217:00 amRNSMercia announces new direct investment
21st Oct 20217:00 amRNSPublication of newsletter
14th Sep 202110:21 amRNSResult of AGM
14th Sep 20217:00 amRNSAGM Statement
3rd Sep 20217:00 amRNSInvestment into Locate Bio
10th Aug 20217:00 amRNSMercia accredited to deliver Recovery Loan Scheme
4th Aug 20217:00 amRNSnDreams appoints new Non-executive Chair
30th Jul 20217:00 amRNSPublication of Annual Report and Notice of AGM
15th Jul 20217:00 amRNSNotification of Major Holdings
12th Jul 20217:00 amRNSGrant of Options
8th Jul 20212:56 pmRNSDirector/PDMR Dealings
6th Jul 20217:00 amRNSPreliminary results
24th Jun 20217:00 amRNSInvestor Presentation
23rd Jun 20213:16 pmRNSPerformance fee entitlement and trading update
10th May 20217:00 amRNSPublication of "The Insight" Newsletter
15th Apr 20217:00 amRNSNotice of Results
12th Apr 20217:00 amRNSVirtual shareholder event
6th Apr 20212:37 pmRNSMyHealthChecked plc signs major contract
5th Mar 202112:46 pmRNSNotification of Major Holdings
4th Mar 20214:09 pmRNSDirector/PDMR Dealings
3rd Mar 20217:00 amEQSEdison Investment Research Limited: Mercia Asset Management (MERC): The UK's top regional investor
1st Mar 20213:31 pmRNSTrading Update
1st Mar 20213:27 pmRNSSale of Oxford Genetics Limited
23rd Feb 20217:00 amRNSSoccer Manager receives £3.0million investment
2nd Feb 20217:00 amRNSSoftware and eCommerce portfolio update
29th Jan 20217:00 amRNSChange of Auditor
8th Dec 20207:00 amRNSQuarterly newsletter
2nd Dec 20207:00 amRNSPerformance fee entitlement
1st Dec 20207:00 amRNSInterim Results
27th Nov 20207:00 amRNSInvestor Presentation
6th Nov 20207:00 amRNSNotice of Results and Investor Presentations
3rd Nov 20207:00 amRNSBoard Appointment
30th Oct 20207:30 amRNSNew direct investment into Sense Biodetection
19th Oct 20207:00 amRNSSuccessful exit of Clear Review
7th Oct 20207:00 amRNSWarwick Acoustics Update
25th Sep 20207:00 amRNSDirector/PDMR Dealings
24th Sep 202010:29 amRNSResult of AGM
24th Sep 20207:00 amRNSAGM Statement
18th Sep 20207:00 amRNSLife Sciences’ Portfolio Update
24th Aug 20207:00 amRNSGrant of Options
31st Jul 20207:03 amRNSPublication of Annual Report
29th Jul 20202:31 pmRNSDirector/PDMR Dealings
14th Jul 20207:00 amRNSPreliminary results
9th Jul 20207:00 amRNSSale of The Native Antigen Company
1st Jul 20207:00 amRNSPortfolio company MIP Diagnostics raises £5.1m
11th Jun 20207:00 amRNSNotice of Results
27th May 202011:08 amRNSMercia accredited by BBB under CBILS
14th May 20207:00 amRNSMedherant partners with Cycle Pharmaceuticals
6th May 20207:00 amRNSInvestment into OXGENE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.